足球在线买球

足球在线买球 Pipeline Pipeline

ONCOLOGY
PRE-CLINICAL
IND ENABLING
PH. I
PH. II
PH. III
STP705
Non-Melanoma Skin Cancer
Intra-tumoral
STP705
Solid Liver Tumors*
Intra-tumoral
STP705
Bladder Cancer
Intra-tumoral
STP707
Solid Tumors
Basket Study, IV
STP778
Solid Tumors
IV
STP355
Solid Tumors
IV
STP302
Colon Cancer
IV/Intratumoral
STP902
Breast Cancer
IV
ANTI-FIBROSIS
PRE-CLIN.
IND ENABLING
PH. I
PH. II
PH. III
STP705
Hypertrophic Scar Reduction
Intradermal
STP705
Keloid Scarless Healing
Intradermal
STP707
Liver Fibrosis (PSC) *
IV
STP707
Liver Fibrosis (NASH)
IV
STP707
Lung Fibrosis
Inhalation/IV
ANTI-VIRAL
PRE-CLINICAL
IND ENABLING
PH. I
PH. II
PH. III
STP702
Influenza
Inhalation/IV
STP908
Coronavirus
Inhalation/IV
GALAHEAD
PRE-CLINICAL
IND ENABLING
PH. I
PH. II
PH. III
STP122G
Anticoagulant Therapy
Subcu
STP133G
Cardiometabolic Diseases
Subcu
STP144G
Complement-Mediated Diseases
Subcu
Notes:
* Orphan Drug Designation;
PSC: Primary Sclerosing Cholangitis;
NASH: Nonalcoholic Steatohepatitis

Non-Melanoma Skin Cancer (NMSC)

Non-Melanoma Skin Cancer (NMSC) originates in the basal cells or squamous cells of the epidermal layer of the skin. Basal Cell Carcinoma (BCC) accounts for 75-80% of all skin cancers while squamous cell carcinoma (SCC) accounts for ~20%. TGF-β1 has been identified as a major factor that promotes epithelial cell proliferation and is a critical regulator of NMSC development and progression in humans. COX-2 is also required by the myeloid suppressor cells to produce an immunosuppressive molecule (arginase-1) that promotes the invasion and angiogenesis of human NMSC cells. STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size.

CCA
(Liver Cancer)

Cholangiocarcinoma (CCA) is a cancer that can form in the bile ducts of the liver. It is a rare disease but while it typically occurs in patients over 50 years old it can occur at any age. The tumor is very difficult to treat. It is often caused by inflammation and many PSC patients will eventually develop CCA. Age (>50) and smoking are significant additional risk factors for the disease.

HCC
(Liver cancer)

HCC is a cancer within the liver. It is most often caused by liver damage induced by Cirrhosis caused by infections from viruses such as Hepatitis B and Hepatitis C. Treatment options currently involve surgery, liver transplantation, chemotherapy and/or or radiation treatment. Sorafenib (Nexavar; a kinase inhibitor) may slow disease progression in advanced cases but there is a need for efficacious therapeutics that produce a cure.

HCC (IO)

In patients with liver cancer who fail to show improvement when treated with Sorafenib the USFDA has approved treatment with the mAb therapeutic Opdivo (Nivolumab; a PD-1 checkpoint inhibitor). 足球在线买球 is working to develop siRNA therapeutics that augment the action of the immune checkpoint inhibitors to improve the clinical outcomes for patients with liver cancer (HCC).

Other Cancers

足球在线买球 has active programs to identify siRNAs that can silence key driver genes of importance in tumors such as Pancreatic and other cancers. 足球在线买球 also has active programs to find siRNAs that can augment the activity of approved therapeutics in these indications. PNP can deliver 2 siRNAs to the same cells within the same tissues and so we can target multiple pathways within the cancer cells – preventing them from escaping therapeutic pressure by expressing genes in a resistance mechanism.

PSC or Primary Sclerosing Cholangitis

PSC is a disease affecting the bile ducts of the liver. In this disease inflammation progressively produces scarring within the bile ducts. The disease progresses slowly but the scarring can result in tumors within the liver or bile ducts and can lead to liver failure. The only cure is a liver transplant but PSC can sometimes reoccur within the transplanted liver.